Migraine is a painful neurologic disorder with premonitory symptomatology that can include disturbed appetite. Migraine pathophysiology involves abnormal activation of trigeminocervical complex (TCC) neurons. Neuropeptide Y (NPY) is synthesized in the brain and is involved in pain modulation. NPY receptors are present in trigeminal ganglia and trigeminal nucleus caudalis suggesting a role in migraine pathophysiology. The present study aimed to determine the effect of systemic administration of NPY on TCC neuronal activity in response to dural nociceptive trigeminovascular activation. We performed in vivo electrophysiology in anesthetized rats, administered NPY (10, ), NPY Y 2 , and Y 5 receptor agonists, and the NPY Y 1 receptor antagonist had no significant effects on nociceptive dural-evoked neuronal firing in the TCC or spontaneous trigeminal firing. This study demonstrates that NPY dose dependently inhibits dural-evoked trigeminal activity, through NPY Y 1 receptor activation, indicating antinociceptive actions of NPY in a migraine animal model. Based on the role of NPY in appetite regulation, it is possible that disruption of the NPY system might explain changes of appetite in migraineurs.
Introduction
Migraine is considered a complex brain disorder 3, 22 and is the sixth most common cause of disability in the world. 19 Neuroimaging studies in the premonitory phase, which represents the earliest clinical manifestations of the migraine attack, 23 have demonstrated hypothalamic activation, 32 while a somewhat different hypothalamic site is activated during the attack. 13 This is in agreement with earlier animal studies, 6, 7, 11, 31 establishing the hypothalamus as an important brain area in migraine pathophysiology. Disturbed appetite, such as thirst, hunger, or food craving, or feeding schedules have been reported anecdotally as triggers, 9 or as symptoms in the premonitory phase of the migraine attack. 14, 18, 43 Importantly, these premonitory symptoms are regulated in part by the hypothalamus that in turn implicates appetite-related neuropeptides, including neuropeptide Y (NPY). NPY is a peptide hormone known to be involved in pain modulation, 24 appetite control, and circadian rhythm synchronization 30, 39 and is present in central and peripheral nervous systems, but is most abundantly expressed in the brain. In the human brain, NPY expression is highly concentrated in hypothalamic nuclei, basal ganglia, and limbic system. 1 NPY potentially acts on six G protein-coupled receptor subtypes (Y [1] [2] [3] [4] [5] [6] , with the NPY Y 3 receptor not yet cloned. The NPY y 6 receptor only exists as a functional receptor in the mouse and rabbit. 53 The NPY Y 4 receptor mRNA is the least abundant and has the most restricted distribution pattern of all NPY receptor subtypes in the central nervous system. 40 In addition, the available agonist for the human NPY Y 4 receptor has a short mean half-life of only approximately 6 minutes, limiting its bioactivity in vivo. 2 NPY has been shown to be involved in antinociception in different pain models, 28, 29, 38 although not studied yet in migraine. NPY causes vasoconstriction of human middle meningeal and cerebral arteries 16, 25 and inhibits plasma protein extravasation through NPY Y 2 receptors. 52 These data suggest that NPY could play an important role in the pathophysiology of primary headache disorders. In the present study, we used an animal model of acute dural nociceptive activation of the trigeminovascular system, which has been shown to represent a valid model to study migraine neurobiology and has reliably predicted clinical efficacy of many therapeutics, such as triptans. 5, 8 We determined the effects of 40 and these receptors have a major role in hypothalamic appetite control. 53 Some data have been presented previously in preliminary form. 34 , intravenous infusion; Abbott Animal Health, Abbott Park, IL). During electrophysiological recording, the animals were paralyzed with pancuronium bromide (Pavulon, Hospira, Inc., Lake Forest, IL), 0.4 mg initially, and maintained with 0.2 mg every 30 minutes. The animals were monitored during the surgical procedure for changes in body temperature, respiratory rate, and blood pressure as described previously. 4 After fixation of the skull in a stereotaxic frame (Kopf Instruments, Tujunga, CA), rats were ventilated (Ugo Basile, Comerio, Italy) with oxygen-enriched air, 2 to 2.5 ml, 80 to 100 strokes per minute, and end-tidal CO 2 was monitored (CapStar-100; CWE Inc, Ardmore, PA) and kept between 3.5% and 4.5%. Arterial blood pressure and end-tidal CO 2 were displayed and recorded on a personal computer using an online data analysis system (Power 1401) and Spike2 v5.21 software (Cambridge Electronic Design, Cambridge, United Kingdom). At the end of each experiment, animals were killed with a lethal dose of intravenously administered pentobarbital and phenytoin sodium (Euthasol; Virbac AH, Inc, Fort Worth, TX).
Middle meningeal artery and trigeminocervical complex exposure
To gain access to the dura mater and middle meningeal artery (MMA), the skull was exposed and a craniotomy of the parietal bone was performed with saline-cooled drilling and the area was covered in mineral oil. For access to the trigeminocervical complex (TCC), the muscles of the dorsal neck were separated, a cervical (C1) laminectomy was performed and the dura mater was incised to expose the brainstem at the level of the caudal medulla oblongata. A piezoelectric motor-driven microelectrode positioner attached to a micromanipulator was used to locate the optimal recording site, allowing movements of the recording electrode in 5-mm steps. After completing the surgery, the animals were left to stabilize for at least 1 hour before electrophysiological recordings.
Stimulation of the MMA and recording from the TCC
After removal of the parietal bone within the cranial window, a bipolar stimulating electrode (NE200; Rhodes Medical Instruments, Summerland, CA) connected to a stimulus isolation unit (SIU5A; Grass Instruments, Quincy, MA) was placed on the intact dura mater adjacent to the MMA for electrical stimulation of the perivascular afferents of the trigeminal nerve (Fig. 1A) . Stimulation of primary trigeminal afferents was performed with supramaximal square-wave pulses generated by a Grass S88 stimulator (GrassInstruments, USA). Dural nociceptive neurons in the TCC were identified by applying square-wave electrical stimuli (8-15 V, 0.15-0.25 milliseconds, 0.4-0.5 Hz, 20 sweeps) to the dura mater. These stimulation parameters were able to activate trigeminal Ad fibers, with approximate latencies between 3 and 20 milliseconds, and less frequently C fibers, with latencies .20 milliseconds and up to 80 milliseconds, which innervate the dura mater.
Extracellular recordings were made from neurons in the TCC, activated by dural stimulation, with cutaneous facial receptive fields (Fig. 1B) , using tungsten microelectrodes (World Precision Instruments, Sarasota, FL; impedance 0.5-1.0 MV, measured at 1 kHz in 0.9% saline, with tip diameter of 0.5 mm). The signal from the recording electrode attached to a high-impedance headstage preamplifier (NL100AK; Neurolog, Digitimer, Welwyn Garden City, Hertfordshire, United Kingdom) was fed through an AC preamplifier (Gain x2000; Neurolog NL104). The signal was then band-pass filtered (Neurolog NL126) from 300 Hz to 20 kHz and passed through a Hum Bug 60 Hz noise eliminator (Quest Scientific, Vancouver, BC, Canada) for removal of line interference before further amplification using an AC-DC second-stage amplifier (Neurolog NL106) with a gain range of 320 to 390 (total gain used approximately 25,000-40,000 Hz). The obtained electrical signal was then fed through a gated amplitude discriminator (Neurolog NL201) and an analog-to-digital converter (Power 1401; Cambridge Electronic Design, Cambridge, United Kingdom) and to a microprocessor-based personal computer (Dell Latitude) using Spike 2 v5.21 software (Cambridge Electronic Design) where the signal was processed and stored. Additionally, it was fed to a loudspeaker through a power amplifier for audio monitoring (Neurolog NL120) and displayed on analog and digital storage oscilloscopes (Goldstar, LG Precision, Seoul, Korea; and Metrix Electronics, Hampshire, UK, respectively) to assist isolation of action potentials from adjacent cell activity and noise.
Characterization of neurons
Neurons were characterized for their cutaneous and deep receptive fields. The cutaneous receptive field was assessed in all 3 territories of the trigeminal innervation and identified as the recording electrode was advanced in the spinal cord. The receptive field was assessed for both nonnoxious inputs, with gentle brushing using a cotton tip applicator, and noxious inputs, with pinching with forceps that was painful when applied to humans. When a neuron sensitive to the stimulation of the ophthalmic (V1) dermatome of the trigeminal nerve was identified, it was tested for convergent input from the dura mater.
Experimental design
Trains of 20 stimuli were delivered at 5-minute intervals to assess the baseline response to dural electrical stimulation. Responses were analyzed using poststimulus histograms with a sweep length of 100 milliseconds and a bin width of 1 milliseconds that separated Ad-fiber-activated (3-20 milliseconds) and C-fiberactivated (20-80 milliseconds) firing. Spontaneous activity (spikes per second, Hz) was recorded for 150 s preceding the dural stimulation using peristimulus histograms. Background activity was analyzed as cumulative rate histograms in which neuronal activity gated through the amplitude discriminator was collected into successive bins. When stable baseline values of the stimulus-evoked responses were achieved (mean of 3 stimulation series that would not differ more than 10%) and cutaneous and deep receptive field inputs from the ophthalmic division of the trigeminal nerve were obtained, responses were tested for up to 60 minutes after pharmacological or vehicle intervention.
Drugs
TCC neuronal responses to electrical dural afferent stimulation were tested with NPY human (Sigma-Aldrich) in a dosage of 10 mg·kg 21 (n 5 6), 30 mg·kg 21 (n 5 9), and 100 mg·kg 21 (n 5 8). The dose of NPY at 10 mg·kg 21 (intravenously) was chosen based on studies of experimental vasodilation in the dura mater 49 and escalated thereafter for a dose-response effect.
To (n 5 5) was administered alone using the same scheme described above. The optimal dose of the antagonist was derived from preliminary experiments showing 30 mg·kg 21 produced a maximum blood pressure increase of 11 6 1%. Sterile water alone was used as the vehicle control group (n 5 7) and naratriptan in a dosage of 10 mg·kg 21 (n 5 6) as a positive control to these responses. All drugs were dissolved in sterile water.
Postsurgical examination of tissue
At the end of the experiment and after terminal anesthesia, an electrothermolytic lesion was made in the TCC by passing a current down the recording electrode (4-6 mA for 60 s) to confirm the location of the recording electrode. The brain and cervical spinal cord were removed. Serial 60-mm-thick coronal sections were cut from the medulla oblongata and C1-C3 spinal segments, stained for cresyl violet, and visualized under the light microscope (Axioplan Microscope; Carl Zeiss GmbH, Jena, Germany), using the rat brain atlas Paxinos and Watson, 2005 41 for reference.
Statistical analysis
Data collected for Ad fibers represent the normalized data for the number of cells firing over a 10-milliseconds time period in the region 4 to 20 milliseconds poststimulation over the 20 collections and expressed as mean 6 SEM. Spontaneous activity was measured in cell firings per second (Hz). Statistical analysis was performed using IBM SPSS 20.0 software. To measure whether there was a significant effect across the 60-minutes time course within a drug group of animals, we used analysis of variance for repeated measures with Bonferroni post hoc correction for multiple comparisons. If Mauchly test of sphericity was violated, appropriate corrections to degrees of freedom were made according to Greenhouse-Geisser. 17 Student paired t test was used for post hoc analysis of the significance of individual time points, using the average of the 3 baselines for comparison. Statistical significance was assumed at P , 0.05.
Results

Electrophysiological data
Recordings were made from a total of 63 neurons in 57 rats. Animals studied had a mean body weight of 319 6 3.2 g. Extracellular recordings in the TCC were made from widedynamic-range neurons, responsive to dural (MMA) stimulation (Fig. 1A) , and with cutaneous receptive fields in the ophthalmic division (V1) of the trigeminal nerve (Fig. 1B) . Most neurons were located in lamina V of the dorsal horn at the level of the cervicomedullary junction (with a few neurons in laminae III-IV), at an average depth of 476 6 27 mm, and the electrode placement was confirmed in all animals by an electrothermolytic lesion in the TCC (Fig. 1C, D) . Neurons responding to dural electrical stimulation responded with an average latency of 10.8 6 0.2 milliseconds (range 4-20 milliseconds, an example of evoked neuronal firing can be seen in Fig. 1E ) and hence were classified as Ad fibers. The mean ongoing spontaneous firing rate was 23.8 6 2.0 Hz with most neurons responding between 10 and 20 Hz; this is within the same range as that demonstrated in previous studies. 4 
Controls
Intravenous injection of sterile water (vehicle control) had no significant effect on Ad-fiber responses (F 3.1,18.8 5 0.9; P 5 0.42) and ongoing spontaneous activity (F 1.8,10.9 5 0.3; P 5 0.72) of trigeminal second-order neurons during the 60-minutes time period.
Naratriptan 10 mg·kg 21 (Sigma-Aldrich) was also tested in another group of animals as a positive control for inhibition of second-order neurons. 21 Extracellular recordings showed a significant decrease of dural-evoked nociceptive responses (F 2.2,10.9 5 3.9; P 5 0.048) throughout the 60 minutes, reaching a maximum inhibition of 27% at 30 minutes (t 5 5 3.592; P 5 0.016) and 60 minutes (t 5 5 4.663; P 5 0.006). Ongoing spontaneous background activity was also significantly reduced (F 2.1,10.5 5 12.4; P 5 0.002) within the TCC after naratriptan administration across the 60-minutes cohort. A maximum inhibition of 58% was achieved at 60 minutes when compared with the baseline (t 5 5 4.472; P 5 0.007). and 100 mg·kg 21 ) did not return to baseline 60 minutes or 90 minutes after the administration (data not shown).
NPY dose dependently inhibits neurotransmission in
NPY Y 1 receptor agonist significantly reduces the activation of the trigeminovascular system
To dissect the specific NPY receptor that mediates this inhibitory response in the trigeminovascular system, we also administered selective agonists. The NPY Y 1 receptor agonist (30 mg·kg 21 ) significantly reduced the dural-evoked neuronal firing (F 8,72 5 3.9; P 5 0.001), reaching a maximum inhibition of approximately 22% at 15 minutes (t 9 5 4.419; P 5 0.002). It also significantly reduced the ongoing spontaneous responses (F 8,72 5 2.4; P 5 0.022), with the greatest point of inhibition at 45 minutes, by 29% below baseline firing (t 9 5 2.545; P 5 0.031). Administration of the NPY Y 2 receptor agonist (30 mg·kg
21
) had no significant effect on nociceptive dural-evoked firing (F 1.6,8.1 5 0.3; P 5 0.70) or ongoing spontaneous neuronal firing (F 1.9,9.9 5 1.0; P 5 0.386).
In a pilot study using the NPY Y 5 receptor agonist (30 mg·kg
), there was no significant difference in neuronal firing compared with baseline values (data not shown); thus, we decided to perform the next experiments using a dose of 100 mg·kg 21 . NPY Y 5 receptor agonist (100 mg·kg Taken together, these data demonstrate that NPY is able to inhibit the effects of dural-evoked trigeminovascular activation in a dose-dependent manner ( Fig. 2A, B) and these effects seem to be specific to the NPY Y 1 receptor (Fig. 2C, D) . 
Blood pressure effect
In all experiments, blood pressure was at physiological levels (92.6 6 2.4 mm Hg) before injections. ), which significantly decreased neuronal responses across the 60-min study. Vehicle has no effect on responses. (B) Bar graph of the maximum effect at the "30-minutes time point" of the change from baseline of dural-evoked Ad-fiber activity in the TCC. NPY (10-100 mg·kg 21 ) dose dependently inhibited dural-evoked neuronal responses, with both 30 and 100 mg·kg 21 significantly inhibiting dural-evoked Ad-fiber activity in the TCC. Water for injection (control) had no effect and naratriptan (10 mg·kg and for the following 60 minutes can be seen in Fig. 3 . Blood pressure slowly returned to baseline levels within 15 minutes independent of the maximal dural-evoked and spontaneous TCC neuronal inhibition, which occurred at 60 minutes postinjection.
NPY Y 1 receptor agonist (30 mg·kg 21 ) significantly increased the mean arterial blood pressure, maximally by 67 6 5% (t 9 5 17.720; P 5 0.000), slowly returning to baseline after 16 6 5 minutes (t 9 5 3.149; P 5 0.012). However, the NPY Y 2 and the NPY Y 5 receptor agonist had no significant effects on blood pressure. The NPY Y 1 receptor antagonist (30 mg·kg
21
) reached a maximum increase of 11 6 1% (t 4 5 8.948; P 5 0.001) after injection, returning to preinjection values after 14 6 2 minutes (t 4 5 4.740; P 5 0.009). Naratriptan decreased the blood pressure by 8 6 5% (t 5 5 1.49; P 5 0.195) after injection and never returned to preinjected blood pressure values.
Discussion
The data demonstrate that NPY can modulate nociceptive trigeminovascular transmission in second-order neurons of the TTC after peripheral systemic administration. This effect could be mimicked by an NPY Y 1 receptor agonist but not by NPY Y 2 , and Y 5 receptor agonists. Moreover, there was no resting effect of the NPY Y 1 receptor on ongoing spontaneous trigeminal firing as evidenced by no effect of an NPY Y 1 receptor antagonist, and consistent with the modest response and lack of a dose-effect for NPY itself. These data are consistent with the existence of an inhibitory NPY Y 1 receptor in the TTC. These results are in agreement with the antinociceptive role of NPY in other animal models of different pain states.
Our findings reveal a potential involvement of NPY in migraine pathophysiology, through its ability to modulate the firing of duralevoked nociceptive second-order trigeminovascular neurons. These data contrast with previous studies that also used dural nociceptive stimulation. In these previous experiments, neuropeptide levels were measured in the extracranial vasculature, taken from external jugular vein blood, after superior sagittal sinus stimulation and were unchanged, 55 in contrast to calcitonin gene-related peptide 55 and pituitary adenylate cyclase-activating peptide. 54 However, this may reflect the locus of release and action in the central nervous system in contrast to the more widespread release of other neuropeptides involved in migraine. For example, localized release of NPY within hypothalamic nuclei, where we know it is released during feeding and impact migraine symptoms, would not be detected in such assays. It is also important to reflect that NPY readily gets into the brain, and our data demonstrate that it is able to attenuate the responses of second-order trigeminovascular neurons to dural-evoked stimulation.
A further aim was to investigate whether NPY exerts tonic antinociceptive control of TCC neurons, by administering an NPY Y 1 receptor antagonist in our model. Spinal NPY is known to exert a tonic, long-lasting inhibitory control of spinal nociceptive transmission, as demonstrated by NPY knockdown or intrathecal administration studies. 45 We did not see an effect on neuronal firing after NPY Y 1 antagonist administration, which suggests that NPY does not exert a tonic control of TCC neuronal firing.
Concerning the cardiovascular effects in our study, the inhibitory response of NPY is not due to blood pressure changes since the time course of blood pressure elevation is different from the inhibition of the trigeminal neurons within the TCC. This is confirmed when the blood pressure returns to baseline values at some point of the study and the TCC neuronal firing is significantly inhibited across the 60-min study.
In our study, we chose to administer NPY systemically. This allowed us to directly translate findings into the clinical setting for potential therapeutics, and because we know NPY is able to cross the blood-brain barrier, 27 it suggests it is likely to acting centrally. Based on this probable action in the brain, we believe the most likely targets in modulating trigeminovascular nociceptive transmission in this study are at the level of the hypothalamus and also directly on the TCC neurons. We have tried to rationalize these potential sites of action with what we know of NPY and how it might fit into a role in migraine pathophysiology. Reported migraine triggers (skipping meals) or symptoms (appetite changes) might act through NPY because altered feeding behavior is able to interfere with NPY pathways. For example, NPY mRNA expression is upregulated by fasting in the hypothalamic arcuate nucleus (ARC) 48 ; NPY Y 1 receptor mRNA is elevated in the hypothalamus in response to fasting and food restriction 50 ; and following food deprivation, NPY is released from ARC-projecting neurons into the hypothalamic paraventricular nucleus (PVN) in vivo. 26 The PVN is a pivotal nucleus with secondorder neurons that integrates signals from ARC first-order neurons (such as NPY-containing neurons), and then sends downstream information to the nucleus tractus solitarii (NTS) to control appetite. 10 Specific hypothalamic nuclei are thought to have a major role in migraine pathophysiology. 33 It has been shown that PVN modulates basal and nociceptive meningealevoked activity of trigeminal neurons, containing neurons known to project directly to the trigeminal nucleus caudalis. 42, 46 Taking into consideration that NPY activity within the ARC-PVN neural circuit is seen as a homeostatic response to perturbations of energy balance, our results showing an inhibition of dural-evoked nociception and spontaneous TCC neuronal firing might indicate that NPY could be acting within the PVN to modulate the TCC through direct projections.
In addition to this, ARC neurons project to many pain modulatory nuclei in the brainstem, including the periaqueductal gray, nucleus tractus solitarii, dorsal raphe nucleus, and locus coeruleus, 44 with NPY-immunoreactive neuronal projections from the ARC to dorsal raphe nucleus and locus coeruleus in the rat. 51 Moreover, intra-ARC administration of NPY exerts an antinociceptive effect in intact rats and in rats with inflammation through NPY Y 1 receptor activation. 29 Because ARC contains a high concentration of NPY-producing neurons and NPY receptors, systemic NPY in our study could also act directly in the ARC with further actions either in the PVN or other pain modulation nuclei to induce inhibition of nociceptive activation of trigeminovascular neurons.
In conclusion, hypothalamic nuclei are in key positions to mediate the triggering of migraine and trigeminovascular activation, modulating migrainous symptoms through appetite changes. In this study, we show that NPY, through its NPY Y 1 receptor, may be involved in such a pathway. The data offer further pharmacologic therapeutic targets to those currently under development, 20 although there is a chance of increased appetite with the NPY Y 1 receptor agonist approach, which could be offset by chronic systemic administration of low doses of an NPY Y 1 agonist. Investigating the pathophysiological mechanisms taking place during the earlier phase of the migraine attack is clearly important to understand migraine and its associated symptoms.
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